1) Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine : the EVOLVE-1 randomized clinical trial. JAMA Neurol 2018 ; 75 : 1080-1088
2) Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine : results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia 2018 ; 38 : 1442-1454
3) Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine : The randomized, double-blind, placebo-controlled REGAIN study. Neurology 2018 ; 91 : e2211-e2221
4) Mulleners WM, Kim BK, Lainez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER) : a multicentre, randomised, double-blind, placebo-controlled, phase 3 b trial. Lancet Neurol 2020 ; 19 : 814-825
5) Sakai F, Ozeki A, Skljarevski V. Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine : A phase 2 randomized controlled clinical trial. Cephalalgia Reports 2020 ; 3 : 1-10
6) Goadsby PJ, Reuter U, Hallstrom Y, et al. A Controlled Trial of erenumab for episodic migraine. N Engl J Med 2017 ; 377 : 2123-2132
7) Goadsby PJ, Reuter U, Hallstrom Y, et al. One-year sustained efficacy of erenumab in episodic migraine : Results of the STRIVE study. Neurology 2020 ; 95 : e469-e479
8) Dodick DW, Ashina M, Brandes JL, et al. ARISE : a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 2018 ; 38 : 1026-1037
9) Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful : a randomised, double blind, placebo-controlled, phase 3b study. Lancet 2018 ; 392 : 2280-2287
10) Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine : a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2017 ; 16 : 425-434
11) Ashina M, Goadsby PJ, Reuter U, et al. Long-term efficacy and safety of erenumab in migraine prevention : Results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol 2021 ; 28 : 1716-1725
12) Sakai F, Takeshima T, Tatsuoka Y, et al. A randomized phase 2 study of erenumab for the prevention of episodic migraine in Japanese adults. Headache 2019 ; 59 : 1731-1742
13) Takeshima T, Sakai F, Hirata K, et al. Erenumab treatment for migraine prevention in Japanese patients : Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study. Headache 2021 ; 61 : 927-935
14) Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine : a randomized clinical trial. JAMA 2018 ; 319 : 1999-2008
15) Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 2017 ; 377 : 2113-2122
16) Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS) : a randomised, double blind, placebo-controlled, phase 3b trial. Lancet 2019 ; 394 : 1030-1040
17) Sakai F, Suzuki N, Kim BK, et al. Efficacy and safety of fremanezumab for episodic migraine prevention : Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 2021 ; 61 : 1102-1111
18) Sakai F, Suzuki N, Kim BK, et al. Efficacy and safety of fremanezumab for chronic migraine prevention : Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 2021 ; 61 : 1092-1101
19) Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine : a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 2020 ; 40 : 241-254
20) Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine : PROMISE-2. Neurology 2020 ; 94 : e1365-e1377